Mode of Action of Tacrolimus (FK506): Molecular and Co

Therapeutic Drug Monitoring 17, 584-591 DOI: 10.1097/00007691-199512000-00007

Citation Report

#	Article	IF	CITATIONS
1	Tacrolimus. Drugs, 1997, 54, 925-975.	4.9	281
2	Clinically Significant Drug Interactions with New Immunosuppressive Agents. Drug Safety, 1997, 16, 267-278.	1.4	122
3	Identification of a 37 kDa Tacrolimus, Sirolimus and cyclosporine binding immunophilin possessing glyceraldehyde 3-phosphate dehydrogenase activity isolated from the JURKAT T cell line. Clinical Biochemistry, 1997, 30, 129-133.	0.8	13
4	Gender Differences in Autoimmune Diseases: Estrogen Increases Calcineurin Expression in Systemic Lupus Erythematosus. Clinical Immunology and Immunopathology, 1998, 89, 171-180.	2.1	58
5	Cyclosporine heart transplantation. Transplantation Proceedings, 1998, 30, 1881-1884.	0.3	22
6	FK506 antagonizes apoptosis and c-jun protein expression in neuronal cultures. NeuroReport, 1998, 9, 2077-2080.	0.6	41
7	Urinary excretion of aquaporin-2 in disorders of water metabolism. Nephrology Dialysis Transplantation, 1998, 13, 1615-1616.	0.4	3
8	Autoantibodies to FK506 Binding Protein 12 (FKBP12) in Autoimmune Diseases. Autoimmunity, 1999, 29, 159-170.	1.2	7
9	Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles. Clinical Transplantation, 1999, 13, 209-220.	0.8	115
10	Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology, 1999, 106, 723-728.	2.5	142
11	Immunosuppressants FK506 and rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation. Biochemical Journal, 1999, 344, 803-812.	1.7	11
12	Immunosuppressants FK506 and rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation. Biochemical Journal, 1999, 344, 803.	1.7	5
13	Simultaneous Quantification of Tacrolimus and Sirolimus, in Human Blood, by High-Performance Liquid Chromatography???Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2000, 22, 608-612.	1.0	45
14	Expression of DNA topoisomerases in chronic proliferative kidney disease. Kidney International, 2000, 58, 1603-1612.	2.6	7
15	Tacrolimus: pharmacology and therapeutic uses in dermatology. International Journal of Dermatology, 2000, 39, 721-727.	0.5	31
16	Immunosuppression with FK506 Increases Bone Induction in Demineralized Isogeneic and Xenogeneic Bone Matrix in the Rat. Journal of Bone and Mineral Research, 2000, 15, 1825-1834.	3.1	35
17	Calcineurin: Form and Function. Physiological Reviews, 2000, 80, 1483-1521.	13.1	1,239
18	Mannosylated Lipoarabinomannan AntagonizesMycobacterium tuberculosis–Induced Macrophage Apoptosis by Altering Ca+2â€Đependent Cell Signaling. Journal of Infectious Diseases, 2000, 182, 240-251.	1.9	96

#	Article	IF	Citations
19	Apoptosis in rheumatic diseases. American Journal of Medicine, 2000, 108, 73-82.	0.6	53
20	Tacrolimus. Drugs, 2000, 59, 323-389.	4.9	266
21	Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. Journal of the Neurological Sciences, 2000, 179, 1-33.	0.3	714
22	Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. International Immunopharmacology, 2001, 1, 1009-1024.	1.7	97
23	CYCLOSPORINE AND TACROLIMUS IN DERMATOLOGY. Dermatologic Clinics, 2001, 19, 119-137.	1.0	44
24	Tacrolimus Ointment. American Journal of Clinical Dermatology, 2001, 2, 389-406.	3.3	65
25	Therapeutic Monitoring of Tacrolimus Concentrations in Blood: Semi-Automated Extraction and Liquid Chromatography-Electrospray Ionization Mass Spectrometry. Therapeutic Drug Monitoring, 2001, 23, 239-249.	1.0	50
26	Tacrolimus in Dermatology. Journal of Cutaneous Medicine and Surgery, 2001, 5, 329-335.	0.6	4
27	Tacrolimus in Dermatology. Journal of Cutaneous Medicine and Surgery, 2001, 5, 329-335.	0.6	37
28	The immunosuppressant drug FK506 is a potent trophic agent for human fetal neurons. Developmental Brain Research, 2001, 132, 151-157.	2.1	34
29	Overexpression of FK506-Binding Protein FKBP12.6 in Cardiomyocytes Reduces Ryanodine Receptor–Mediated Ca ²⁺ Leak From the Sarcoplasmic Reticulum and Increases Contractility. Circulation Research, 2001, 88, 188-194.	2.0	137
30	Effect of 10 Pharmacologic Probes on mRNA Levels of Inducible Nitric Oxide Synthetase and Selected Inflammatory Cytokines in a Rat Model of Acute Otitis Media. Acta Oto-Laryngologica, 2002, 122, 255-261.	0.3	11
31	Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus. Clinical Pharmacokinetics, 2002, 41, 813-851.	1.6	272
32	Effect of tacrolimus on endotoxin-induced lung injury in sheep. Respiratory Physiology and Neurobiology, 2002, 130, 89-97.	0.7	1
33	Evidence for a role of nuclear factor-κB in acute hypovolemic hemorrhagic shock. Surgery, 2002, 131, 50-58.	1.0	27
34	Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine-microemulsion. Clinical Transplantation, 2002, 16, 48-54.	0.8	39
35	Tacrolimus inhibits discordant islet xenograft rejection: a study in the pig-to-rat model. Xenotransplantation, 2003, 10, 628-634.	1.6	5
36	Factors affecting variability in distribution of tacrolimus in liver transplant recipients. British Journal of Clinical Pharmacology, 2003, 57, 298-309.	1.1	95

ARTICLE IF CITATIONS Tacrolimus. Drugs, 2003, 63, 1247-1297. 4.9 373 37 Calcineurin Inhibitors in Renal Transplantation. Drugs, 2003, 63, 1535-1548. 64 Changing paradigms in dermatology: proteomics: a new approach to skin disease. Clinics in 39 0.8 7 Dermatology, 2003, 21, 370-374. Severe hemolytic anemia related to production of cold agglutinins following living donor liver 0.3 transplantation: a case report. Transplantation Proceedings, 2003, 35, 399-400. Prevention of the initial host immuno-inflammatory response determines the long-term survival of 42 encapsulated myoblasts genetically engineered for erythropoietin delivery. Molecular Therapy, 2003, 3.7 36 7, 506-514. Ciclosporina A e tacrolimus: uma revisão. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2004, 40, 393-401. 0.3 Combined Excimer Laser and Topical Tacrolimus for the Treatment of Vitiligo: A Pilot Study. 44 0.4 109 Dermatologic Surgery, 2004, 30, 130-135. Prevalence of gingival overgrowth in transplant patients immunosuppressed with tacrolimus. 2.3 Journal of Clinical Periodontology, 2004, 31, 126-131. Myasthenic crisis after the cessation of FK506 in a patient with myasthenia gravis. Journal of 46 1.8 3 Néurology, 2004, 251, 1154-5. Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation. 1.6 708 Clinical Pharmacokinetics, 2004, 43, 623-653. Update on liver transplantation using cyclosporine. Transplantation Proceedings, 2004, 36, 2525-2531. 48 0.3 26 Production of hepatitis B surface antigen-pulsed dendritic cells from immunosuppressed murine hepatitis B virus carrier: evaluation of immunogenicity of antigen-pulsed dendritic cells in vivo. 49 0.8 Immunobiology, 2004, 209, 551-557. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic 50 0.5 30 rejection: Changes in the immune responses. Transplantation, 2004, 77, 532-537. Tacrolimus or Cyclosporine: Which Is the Better Partner for Mycophenolate Mofetil in Heart 64 Transplant Recipients?. Transplantation, 2004, 78, 591-598. Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver 52 1.0 54 Transplantation. Therapeutic Drug Monitoring, 2004, 26, 506-515. Combined Excimer Laser and Topical Tacrolimus for the Treatment of Vitiligo. Dermatologic Surgery, 54 2004, 30, 130-135. Lack of Correlation between Results of ABO-Incompatible Living Kidney Transplantation and Anti-ABO 54 0.5 88 Blood Type Antibody Titers under Our Current Immunosuppression. Transplantation, 2005, 80, 985-988. Effect of tacrolimus in a patient with pure red-cell aplasia. International Journal of Laboratory Hematology, 2005, 27, 67-69.

# 56	ARTICLE Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheterization and Cardiovascular	IF 0.7	CITATIONS
57	Interventions, 2005, 64, 85-90. Future Treatment Options in PBC. Seminars in Liver Disease, 2005, 25, 347-363.	1.8	15
58	Differential Effect of Tacrolimus on Dermal and Intestinal Wound Healing. Journal of Investigative Surgery, 2005, 18, 71-79.	0.6	31
59	Overview of tacrolimus-based immunosuppression after heart or lung transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 119-130.	0.3	76
60	Immunosuppression with FK506 has no influence on fracture healing in the rat. Bone, 2005, 37, 227-233.	1.4	27
61	Tacrolimus Ointment. Drugs, 2005, 65, 827-858.	4.9	53
62	Comparison of the Efficacy and Safety of 0.1% Tacrolimus Ointment with Topical Corticosteroids in Adult Patients with Atopic Dermatitis. Clinical Drug Investigation, 2006, 26, 235-246.	1.1	42
63	Effects of Immunosuppressive and Immunostimulative Treatment on Pancreatic Injury and Mortality in Severe Acute Experimental Pancreatitis. Pancreas, 2006, 33, 174-183.	0.5	29
64	Tacrolimus and quality of life after kidney transplantation - a multicenter study. Clinical Transplantation, 2006, 20, 504-508.	0.8	12
65	Oral health in renal transplant recipients administered cyclosporin A or tacrolimus. Oral Diseases, 2006, 12, 309-314.	1.5	44
66	Effect of tacrolimus and cyclosporine A on suppression of albumin secretion induced by inflammatory cytokines in cultured human hepatocytes. Inflammation Research, 2006, 55, 216-220.	1.6	15
67	Role of Topical Calcineurin Inhibitors on Atopic Dermatitis of Children. Current Medicinal Chemistry, 2007, 14, 1579-1591.	1.2	6
68	Cloned Enzyme Donor Immunoassay Tacrolimus Assay Compared With High-Performance Liquid Chromatography-Tandem Mass Spectrometry and Microparticle Enzyme Immunoassay in Liver and Renal Transplant Recipients. Therapeutic Drug Monitoring, 2007, 29, 584-591.	1.0	33
71	Tacrolimus: A New Option in Therapy-Resistant Chronic External Otitis. Laryngoscope, 2007, 117, 1046-1052.	1.1	26
72	Systemic ciclosporin and tacrolimus in dermatology. Dermatologic Therapy, 2007, 20, 239-250.	0.8	72
73	Successful treatment using tacrolimus plus corticosteroid in a patient with RA associated with MDS. Rheumatology International, 2008, 28, 487-490.	1.5	5
75	How not to be seen: immune-evasion strategies in gene therapy. Gene Therapy, 2008, 15, 239-246.	2.3	32
76	Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. Journal of Dermatology, 2008, 35, 712-718.	0.6	49

#	Article	IF	CITATIONS
77	The effects of over-expression of the FK506-binding protein FKBP12.6 on K+ currents in adult rabbit ventricular myocytes. Pflugers Archiv European Journal of Physiology, 2009, 458, 653-660.	1.3	4
78	Quantification of Tacrolimus in Human Skin Samples and Ointment by LC-MS. Chromatographia, 2009, 70, 581-584.	0.7	6
79	Kidney Graft Function in Long-term Cyclosporine and Tacrolimus Treatment: Comparative Study With Nephrotoxicity Markers. Transplantation Proceedings, 2009, 41, 1660-1665.	0.3	10
80	Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients. Pharmaceutics, 2010, 2, 291-299.	2.0	28
81	Recalcitrant Pemphigus Vulgaris Responding to Systemic Tacrolimus. Dermatology, 2010, 221, 122-126.	0.9	16
82	Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model. Atherosclerosis, 2010, 208, 97-103.	0.4	27
83	Epidermal Cysts in a Tacrolimus Treated Renal Transplant Recipient. Annals of Dermatology, 2011, 23, S182.	0.3	7
84	An Investigation Comparing the Efficacy of Topical Ocular Application of Tacrolimus and Cyclosporine in Dogs. Veterinary Medicine International, 2011, 2011, 1-5.	0.6	34
85	Dermal targeting of tacrolimus using colloidal carrier systems. International Journal of Pharmaceutics, 2011, 404, 159-168.	2.6	67
86	Keratoconjunctivitis Sicca Manifestations in Ocular Graft Versus Host Disease: Pathogenesis, Presentation, Prevention, and Treatment. Seminars in Ophthalmology, 2011, 26, 251-260.	0.8	29
87	Ocular graft-versus-host disease. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 540-547.	1.1	104
88	Inhibitory Effect of Tacrolimus on p38 Mitogen-Activated Protein Kinase Signaling in Kidney Transplant Recipients Measured by Whole-Blood Phosphospecific Flow Cytometry. Transplantation, 2012, 93, 1245-1251.	0.5	14
89	The Effect of Topical FK506 (Tacrolimus) in a Mouse Model of Allergic Rhinitis. American Journal of Rhinology and Allergy, 2012, 26, e71-e75.	1.0	7
90	Putative Calcium Channels CchA and MidA Play the Important Roles in Conidiation, Hyphal Polarity and Cell Wall Components in Aspergillus nidulans. PLoS ONE, 2012, 7, e46564.	1.1	56
91	Immunosuppressants: implications in Orthodontics. Dental Press Journal of Orthodontics, 2012, 17, 55-61.	0.2	4
92	Preparation and <i>In Vitro</i> Evaluation of Tacrolimus-Loaded Ethosomes. Scientific World Journal, The, 2012, 2012, 1-6.	0.8	22
93	Drug-eluting stent restenosis: Effect of drug type, release kinetics, hemodynamics and coating strategy. , 2012, 134, 43-53.		62
94	The effects of tacrolimus on colonic anastomotic healing in rats. International Journal of Colorectal Disease, 2012, 27, 299-308.	1.0	13

ARTICLE IF CITATIONS Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers. Seminars in 116 95 1.6 Arthritis and Rheumatism, 2013, 43, 241-258. Oral tacrolimus as maintenance therapy for refractory ulcerative colitisâ \in "an analysis of outcomes in two London tertiary centres. Journal of Crohn's and Colitis, 2013, 7, e516-e521. 24 Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis. Medical Hypotheses, 97 0.8 24 2013, 81, 901-904. Effective long-term immunosuppression in rats by subcutaneously implanted sustained-release tacrolimus pellet: Effect on spinally grafted human neural precursor survival. Experimental 98 2.0 24 Neurology, 2013, 248, 85-99 Cytokines in graft-versus-host disease and graft-versus-leukemia., 2013, , 357-391. 99 0 PharmGKB summary. Pharmacogenetics and Genomics, 2013, 23, 563-585. 184 Immunosuppression and Monitoring of Rejection in Hand Transplantation. Techniques in Hand and 101 0.3 28 Upper Extremity Surgery, 2013, 17, 208-214. Electroporation as a Method to Induce Myofiber Regeneration and Increase the Engraftment of Myogenic Cells in Skeletal Muscles of Primates. Journal of Neuropathology and Experimental 20 Néurology, 2013, 72, 723-734. 103 Heart and lung transplantation. Current Opinion in Anaesthesiology, 2014, 27, 153-160. 0.9 5 Tacrolimus Exposure and Mycophenolate Pharmacokinetics and Pharmacodynamics Early After Liver 104 1.0 Transplantation. Therapeutic Drug Monitoring, 2014, 36, 46-53. Immunosuppressive Effect of Compound K on Islet Transplantation in an STZ-Induced Diabetic Mouse 105 0.3 11 Model. Diabetes, 2014, 63, 3458-3469. Polymeric Micelle Nanocarriers for the Cutaneous Delivery of Tacrolimus: A Targeted Approach for 2.3 the Treatment of Psoriasis. Molecular Pharmaceutics, 2014, 11, 2989-3001. Proniosome-derived niosomes for tacrolimus topical ocular delivery: In vitro cornea permeation, 107 ocular irritation, and in vivo anti-allograft rejection. European Journal of Pharmaceutical Sciences, 1.9 99 2014, 62, 115-123. Drug-eluting biostable and erodible stents. Journal of Controlled Release, 2014, 193, 188-201. 4.8 Clinical evaluation of the QMS® Tacrolimus Immunoassay. Clinica Chimica Acta, 2014, 431, 270-275. 109 0.5 11 Coronary drugâ€eluting stents: From design optimization to newer strategies. Journal of Biomedical 46 Material's Research - Part A, 2014, 102, 1625-1640. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood, 111 0.6 153 2014, 124, 354-362. Management of Dry Eye in SjŶgren's Syndrome. Current Treatment Options in Rheumatology, 2015, 1, 292-304.

# 113	ARTICLE Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. Transplantation Proceedings, 2015, 47,	IF 0.3	Citations 8
114	2388-2392. Clinical Immunosuppressants Inhibit Inflammatory, Proliferative, and Reprogramming Potential, But not Angiogenesis of Human Pancreatic Duct Cells. Cell Transplantation, 2015, 24, 1585-1598.	1.2	1
115	Tacrolimus prevents laryngotracheal stenosis in an acuteâ€injury rat model. Laryngoscope, 2015, 125, E210-5.	1.1	11
116	Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets. Cureus, 2015, 7, e376.	0.2	16
117	The long-term administration of calcineurin inhibitors decreases antioxidant enzyme activity in the rat parotid and submandibular salivary glands. Life Sciences, 2015, 134, 1-8.	2.0	7
118	Cytotoxic and genotoxic effects of high concentrations of the immunosuppressive drugs cyclosporine and tacrolimus in MRC-5 cells. Experimental and Toxicologic Pathology, 2015, 67, 179-187.	2.1	22
119	Insights into peptidyl-prolyl cis–trans isomerase structure and function in immunocytes. Immunology Letters, 2015, 163, 120-131.	1.1	37
120	Dermatological Manifestations of Kidney Disease. , 2015, , .		0
121	Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC–MS/MS. Bioanalysis, 2015, 7, 1037-1058.	0.6	38
122	An UPLC–MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in peripheral blood mononuclear cells. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 512-517.	1.4	29
123	The effects of tacrolimus on the activity and expression of tissue factor in the rat ovary with ischemia–reperfusion induced injury. Reproductive Biology, 2015, 15, 139-145.	0.9	6
124	Alopecias. , 2015, , 159-167.		0
125	Modeling the effects of commonly used drugs on human metabolism. FEBS Journal, 2015, 282, 297-317.	2.2	29
126	Management of oral Graft versus Host Disease with topical agents: A systematic review. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2016, 21, e72-e81.	0.7	11
127	Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration. Transplant International, 2016, 29, 655-662.	0.8	99
128	Targeting Kv1.3 channels to reduce white matter pathology after traumatic brain injury. Experimental Neurology, 2016, 283, 188-203.	2.0	18
129	Tacrolimus and curcumin co-loaded liposphere gel: Synergistic combination towards management of psoriasis. Journal of Controlled Release, 2016, 243, 132-145.	4.8	98
130	Extended-release tacrolimus tablets for preventing organ transplant rejection. Expert Opinion on Orphan Drugs, 2016, 4, 1079-1086.	0.5	0

#	Article	IF	Citations
131	A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients. Journal of Chromatography A, 2016, 1475, 55-63.	1.8	17
132	Advancements in the management of uveitis. Best Practice and Research in Clinical Rheumatology, 2016, 30, 304-315.	1.4	37
133	Pharmacology of Ocular Therapeutics. , 2016, , .		6
134	Mucoadhesive Polymers and Ocular Lubricants. , 2016, , 269-283.		1
135	Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulmonary Pharmacology and Therapeutics, 2016, 36, 46-52.	1.1	41
136	Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Annals of Oncology, 2016, 27, 1135-1137.	0.6	131
137	Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats. Journal of Physiology and Biochemistry, 2016, 72, 133-144.	1.3	27
138	Fingolimod treatment abrogates chikungunya virus–induced arthralgia. Science Translational Medicine, 2017, 9, .	5.8	57
139	Current Approaches to Treatment of Ocular Graft-Versus-Host Disease. International Ophthalmology Clinics, 2017, 57, 65-88.	0.3	16
140	Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients. Acta Pharmacologica Sinica, 2017, 38, 1195-1204.	2.8	9
141	The safety of non-biological treatments in Ulcerative Colitis. Expert Opinion on Drug Safety, 2017, 16, 779-789.	1.0	29
142	Conjunctival squamous papilloma refractory to interferon α-2b in a patient on systemic immunosuppression (tacrolimus). American Journal of Ophthalmology Case Reports, 2017, 6, 1-3.	0.4	6
143	FKBP8 recruits LC3A to mediate Parkinâ€independent mitophagy. EMBO Reports, 2017, 18, 947-961.	2.0	295
144	Tacrolimus Eye Drops as Adjunct Therapy in Severe Corneal Endothelial Rejection Refractory to Corticosteroids. Cornea, 2017, 36, 1195-1199.	0.9	13
145	Single synchronous delivery of FK506-loaded polymeric microspheres with pancreatic islets for the successful treatment of streptozocin-induced diabetes in mice. Drug Delivery, 2017, 24, 1350-1359.	2.5	29
146	Cytokines in Hematopoietic Stem Cell Transplantation. , 2017, , 219-236.		1
147	Translation in cardiovascular stents and occluders: From biostable to fully degradable. Bioengineering and Translational Medicine, 2017, 2, 156-169.	3.9	14
148	Occult Hepatitis B Virus Reactivation in a Seronegative Stem Cell Transplant Recipient. Infectious Diseases in Clinical Practice, 2017, 25, 97-99.	0.1	0

	CITATION REF	ORT	
#	Article	IF	CITATIONS
149	Natural Products as Source of Anti-Inflammatory Drugs. , 0, , 1661-1690.		4
150	Impairment of early fracture healing by skeletal muscle trauma is restored by FK506. BMC Musculoskeletal Disorders, 2017, 18, 253.	0.8	28
151	Development and characterization of methoxy poly(ethylene oxide)- block -poly(ε-caprolactone) (PEO- b) Tj ETQq Journal, 2017, 25, 258-265.	0 0 0 rgBT 1.2	- /Overlock 17
152	Topical tacrolimus causing gingival hyperplasia: A case report. Dermatologic Therapy, 2017, 30, e12407.	0.8	1
153	Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cellular and Molecular Immunology, 2017, 14, 146-179.	4.8	99
154	FK506, an Immunosuppressive Drug, Induces Autophagy by Binding to the V-ATPase Catalytic Subunit A in Neuronal Cells. Journal of Proteome Research, 2017, 16, 55-64.	1.8	41
155	Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis. Neurological Sciences, 2017, 38, 325-330.	0.9	21
156	Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. International Journal of Nanomedicine, 2017, Volume 12, 1485-1497.	3.3	32
157	Tacrolimus Increases the Effectiveness of Itraconazole and Fluconazole against Sporothrix spp Frontiers in Microbiology, 2017, 8, 1759.	1.5	18
158	Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. Journal of Inflammation, 2017, 14, 26.	1.5	41
159	Tacrolimus as an adjunct to autologous minced muscle grafts for the repair of a volumetric muscle loss injury. Journal of Experimental Orthopaedics, 2017, 4, 36.	0.8	22
160	Tacrolimus Loaded PEG-Cholecalciferol Based Micelles for Treatment of Ocular Inflammation. Pharmaceutical Research, 2018, 35, 117.	1.7	20
161	Quantification of Torque Teno Virus and Epstein-Barr Virus Is of Limited Value for Predicting the Net State of Immunosuppression After Lung Transplantation. Open Forum Infectious Diseases, 2018, 5, ofy050.	0.4	31
162	Tacrolimus Concentration in Saliva of Kidney Transplant Recipients: Factors Influencing the Relationship with Whole Blood Concentrations. Clinical Pharmacokinetics, 2018, 57, 1199-1210.	1.6	12
163	Interdigitating dendritic cell sarcoma of the supraglottic larynx. Otolaryngology Case Reports, 2018, 6, 51-55.	0.0	2
164	The role of immunological testing and intervention in reproductive medicine: A fertile collaboration?. American Journal of Reproductive Immunology, 2018, 79, e12784.	1.2	26
165	Association of the PPARÎ ³ /PI3K/Akt pathway with the cardioprotective effects of tacrolimus in myocardial ischemic/reperfusion injury. Molecular Medicine Reports, 2018, 17, 6759-6767.	1.1	14
166	Erythema dyschromicum perstans: A case report and systematic review of histologic presentation and treatment. International Journal of Women's Dermatology, 2018, 4, 216-222.	1.1	11

#	Article	IF	CITATIONS
167	<i>In Vitro</i> and <i>In Vivo</i> Assessment of FK506 Analogs as Novel Antifungal Drug Candidates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	44
168	Multidimensional improvement in connective tissue diseaseâ€associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by lowâ€dose prednisone and tacrolimus. Respirology, 2018, 23, 1041-1048.	1.3	28
169	Immunomodulatory effect of thymoquinone on atopic dermatitis. Molecular Immunology, 2018, 101, 276-283.	1.0	28
170	Yeast Infections in Solid Organ Transplantation. Infectious Disease Clinics of North America, 2018, 32, 651-666.	1.9	4
171	Current and EmergingÂDrug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs, 2019, 79, 1511-1528.	4.9	35
172	Limited sampling strategy to predict the area under the curve of tacrolimus in Mexican renal transplant pediatric patients receiving Prograf [®] or nonâ€innovator formulations. Pediatric Transplantation, 2019, 23, e13595.	0.5	5
173	Tacrolimus restores the high―and lowâ€pressure baroreflex control of renal sympathetic nerve activity in cisplatinâ€induced renal injury rats. Experimental Physiology, 2019, 104, 1726-1736.	0.9	3
174	Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?. International Journal of Molecular Sciences, 2019, 20, 4710.	1.8	12
175	Cytokines in GVHD and GVL. , 2019, , 293-322.		2
176	Evaluation of the use of tacrolimus ointment for the prevention of hypertrophic scars in experimental model. Anais Brasileiros De Dermatologia, 2019, 94, 164-171.	0.5	4
176 177	Evaluation of the use of tacrolimus ointment for the prevention of hypertrophic scars in experimental model. Anais Brasileiros De Dermatologia, 2019, 94, 164-171. Nonâ€pruritic bullous scabies in an immunosuppressed pediatric patient. Pediatric Dermatology, 2019, 36, 552-553.	0.5	4
	experimental model. Anais Brasileiros De Dermatologia, 2019, 94, 164-171. Nonâ€pruritic bullous scabies in an immunosuppressed pediatric patient. Pediatric Dermatology, 2019, 36,		
177	experimental model. Anais Brasileiros De Dermatologia, 2019, 94, 164-171. Nonâ€pruritic bullous scabies in an immunosuppressed pediatric patient. Pediatric Dermatology, 2019, 36, 552-553. Comparative assessment of efficacy and safety potential of multifarious lipid based Tacrolimus loaded	0.5	4
177 178	experimental model. Anais Brasileiros De Dermatologia, 2019, 94, 164-171. Nonâ€pruritic bullous scabies in an immunosuppressed pediatric patient. Pediatric Dermatology, 2019, 36, 552-553. Comparative assessment of efficacy and safety potential of multifarious lipid based Tacrolimus loaded nanoformulations. International Journal of Pharmaceutics, 2019, 562, 96-104. mTOR inhibitor sirolimus negatively impacts in vitro fertilization outcomes. Journal of Assisted	0.5 2.6	4 36
177 178 179	 experimental model. Anais Brasileiros De Dermatologia, 2019, 94, 164-171. Nonâ€pruritic bullous scabies in an immunosuppressed pediatric patient. Pediatric Dermatology, 2019, 36, 552-553. Comparative assessment of efficacy and safety potential of multifarious lipid based Tacrolimus loaded nanoformulations. International Journal of Pharmaceutics, 2019, 562, 96-104. mTOR inhibitor sirolimus negatively impacts in vitro fertilization outcomes. Journal of Assisted Reproduction and Genetics, 2019, 36, 947-950. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics 	0.5 2.6 1.2	4 36 4
177 178 179 180	 experimental model. Anais Brasileiros De Dermatologia, 2019, 94, 164-171. Nonâ€pruritic bullous scabies in an immunosuppressed pediatric patient. Pediatric Dermatology, 2019, 36, 552-553. Comparative assessment of efficacy and safety potential of multifarious lipid based Tacrolimus loaded nanoformulations. International Journal of Pharmaceutics, 2019, 562, 96-104. mTOR inhibitor sirolimus negatively impacts in vitro fertilization outcomes. Journal of Assisted Reproduction and Genetics, 2019, 36, 947-950. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 2019, 29, 9-17. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. 	0.5 2.6 1.2 0.7	4 36 4 9
177 178 179 180 181	 experimental model. Anais Brasileiros De Dermatologia, 2019, 94, 164-171. Nonâ€pruritic bullous scabies in an immunosuppressed pediatric patient. Pediatric Dermatology, 2019, 36, 552-553. Comparative assessment of efficacy and safety potential of multifarious lipid based Tacrolimus loaded nanoformulations. International Journal of Pharmaceutics, 2019, 562, 96-104. mTOR inhibitor sirolimus negatively impacts in vitro fertilization outcomes. Journal of Assisted Reproduction and Genetics, 2019, 36, 947-950. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 2019, 29, 9-17. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307. Mesenchymal Stem Cell Therapy in Submandibular Salivary Gland Allotransplantation: Experimental 	0.5 2.6 1.2 0.7 1.0	4 36 4 9 374

#	Article	IF	CITATIONS
185	Review of pharmacotherapeutic treatments for primary sclerosingÂcholangitis. Canadian Liver Journal, 2019, 2, 58-70.	0.3	2
186	Notalgia paresthetica: treatment review and algorithmic approach. Journal of Dermatological Treatment, 2020, 31, 424-432.	1.1	20
187	Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome. World Journal of Pediatrics, 2020, 16, 159-167.	0.8	7
188	Roles of glycogen synthase kinase 3 alpha and calcineurin in regulating the ability of sperm to fertilize eggs. FASEB Journal, 2020, 34, 1247-1269.	0.2	9
189	Clickable, acid labile immunosuppressive prodrugs for <i>in vivo</i> targeting. Biomaterials Science, 2020, 8, 266-277.	2.6	16
190	Effects of FK506 on the healing of diaphyseal, critical size defects in the rat femur. , 2020, 40, 160-171.		11
191	Role of FK506 Binding Protein on Tacrolimus Distribution in Red Blood Cells. Pharmaceutical Research, 2020, 37, 143.	1.7	11
192	Prohibitin regulates mTOR pathway via interaction with FKBP8. Frontiers of Medicine, 2021, 15, 448-459.	1.5	6
193	Use of phenytoin for treatment of tacrolimus toxicity with superimposed sepsis. BMJ Case Reports, 2020, 13, e234839.	0.2	5
194	The Effect of Topical Tacrolimus on Pedicled Flap Survival. Annals of Plastic Surgery, 2020, 85, S118-S121.	0.5	3
195	Nr4a1 and Nr4a3 Reporter Mice Are Differentially Sensitive to T Cell Receptor Signal Strength and Duration. Cell Reports, 2020, 33, 108328.	2.9	50
196	COVIDâ€19 in lung transplant recipients: A case series from Milan, Italy. Transplant Infectious Disease, 2020, 22, e13356.	0.7	19
197	Pharmacogenetic—Whole blood and intracellular pharmacokinetic—Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients. PLoS ONE, 2020, 15, e0230195.	1.1	24
198	Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit. Current Treatment Options in Neurology, 2020, 22, 7.	0.7	8
199	Proniosomes: the effective and efficient drug-carrier system. Therapeutic Delivery, 2020, 11, 125-137.	1.2	17
200	Ocular Graft-Versus-Host Disease Topic Review. Current Ophthalmology Reports, 2020, 8, 36-43.	0.5	4
201	Immunosuppressant-Induced Oxidative Stress and Iron: A Paradigm Shift from Systemic to Intrahepatic Abnormalities. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-10.	1.9	12
202	<p>Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions</p> . Clinical Ophthalmology, 2020, Volume 14, 837-852.	0.9	29

#	Article	IF	CITATIONS
203	Graft-Versus-Host Disease (GvHD) Prophylaxis. , 2021, , 153-186.		0
204	Effect of Short-Term Tacrolimus Exposure on Rat Liver: An Insight into Serum Antioxidant Status, Liver Lipid Peroxidation, and Inflammation. Mediators of Inflammation, 2021, 2021, 1-12.	1.4	9
205	Monitoring of gene expression in tacrolimusâ€treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. British Journal of Clinical Pharmacology, 2021, 87, 3851-3862.	1.1	6
206	The Role of Innate and Adaptive Immune Cells in Skeletal Muscle Regeneration. International Journal of Molecular Sciences, 2021, 22, 3265.	1.8	43
207	Effects of Modifications on the Immunosuppressive Properties of Cyclolinopeptide A and Its Analogs in Animal Experimental Models. Molecules, 2021, 26, 2538.	1.7	7
208	Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Reports, 2021, 35, 108959.	2.9	176
209	Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion. Pharmaceuticals, 2021, 14, 353.	1.7	3
210	A polymeric aqueous tacrolimus formulation for topical ocular delivery. International Journal of Pharmaceutics, 2021, 599, 120364.	2.6	19
211	Testicular subcutaneous allografting followed by immunosuppressive treatment promotes maintenance of spermatogonial cells in rainbow trout (Oncorhynchus mykiss). Fish and Shellfish Immunology, 2021, 112, 108-115.	1.6	5
212	Histologic Features of Tacrolimus-induced Colonic Injury. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 118-123.	2.1	9
213	Tacrolimus action pathways in an ointment base for hypertrophic scar prevention in a rabbit ear model. Anais Brasileiros De Dermatologia, 2021, 96, 429-435.	0.5	5
214	Novel Therapeutic Interventions in Systemic Lupus Erythematosus. , 0, , .		0
215	Multiple Adverse Drug Reactions to Calcineurin Inhibitors in a Renal Transplant Patient. Uro, 2021, 1, 180-186.	0.3	2
216	Epstein-Barr Virus-Negative Diffuse Large B-Cell Post-transplant Lymphoma in an Epstein-Barr Virus-Positive Recipient. Cureus, 2021, 13, e18134.	0.2	1
217	Immunosuppressive therapy after solid organ transplantation and the gut microbiota: Bidirectional interactions with clinical consequences. American Journal of Transplantation, 2022, 22, 1014-1030.	2.6	29
218	NFATc1 promotes epithelial-mesenchymal transition and facilitates colorectal cancer metastasis by targeting SNAI1. Experimental Cell Research, 2021, 408, 112854.	1.2	8
219	The Keratinocyte as a Crucial Cell in the Predisposition, Onset, Progression, Therapy and Study of the Atopic Dermatitis. International Journal of Molecular Sciences, 2021, 22, 10661.	1.8	17
221	Phosphodiesterases in Asthma. , 1999, , 87-135.		3

# 222	ARTICLE Cell Survival and Death in Rheumatic Diseases. , 2009, , 379-395.	IF	Citations
223	Topical delivery of Tacrolimus using liposome containing gel: An emerging and synergistic approach in management of psoriasis. Medical Hypotheses, 2020, 142, 109838.	0.8	25
224	Cyclosporine and tacrolimus. Topics in Companion Animal Medicine, 1997, 12, 161-166.	0.1	23
225	PRESENCE OF ANTI-FKBP12 AUTOANTIBODIES IN PATIENTS WITH LIVER ALLOGRAFTS. Transplantation, 1997, 64, 1336-1342.	0.5	7
226	TACROLIMUS IMPAIRS WOUND HEALING. Transplantation, 1998, 65, 813-818.	0.5	47
229	Calcineurin-independent inhibition of KV1.3 by FK-506 (tacrolimus): a novel pharmacological property. American Journal of Physiology - Cell Physiology, 2007, 292, C1714-C1722.	2.1	13
230	Irritant Dermatitis (Irritation). , 2004, , 181-227.		10
231	Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets. PLoS ONE, 2017, 12, e0186364.	1.1	16
232	Drug Repurposing Screens Reveal FDA Approved Drugs Active Against SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	7
233	Calcineurin inhibitors in the treatment of allergic dermatitis. Jornal De Pediatria, 2006, 82, 166-172.	0.9	7
234	Interleukin-17 plays a critical role in the acute rejection of intestinal transplantation. World Journal of Gastroenterology, 2013, 19, 682.	1.4	12
235	Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases. World Journal of Gastroenterology, 2019, 25, 4125-4147.	1.4	47
236	Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model. Pharmaceutics, 2021, 13, 1737.	2.0	7
237	Clinically available immunosuppression averts rejection but not systemic inflammation after porcine islet xenotransplant in cynomolgus macaques. American Journal of Transplantation, 2022, 22, 745-760.	2.6	9
238	Overexpression of FKBP12.6 to influence SR function. , 2000, , 89-99.		0
240	Preclinical Immunotoxicology Assessment of Cytokine Therapeutics. , 2003, , 191-231.		Ο
241	Tacrolimus hemmt die dermale, nicht jedoch die intestinale Wundheilung. Langenbecks Archiv FuÌ^r Chirurgie Supplement, 2003, , 225-227.	0.0	0
242	Immunosuppression in Pancreas Transplantation. , 2004, , 267-347.		3

#	Article	IF	CITATIONS
244	Short-term Effects and Side Effects of Tacrolimus for Behçet's Uveitis. Journal of Korean Ophthalmological Society, 2007, 48, 1654.	0.0	1
247	Cell Survival and Death in Rheumatic Diseases. , 2013, , 382-399.e4.		2
248	Immunosuppressive Medications. , 2014, , 2809-2825.		0
249	Prophylaxis of renal transplant rejection with new chemical immunosuppressants (tacrolimus,) Tj ETQq1 1 0.7843 Opinion in Organ Transplantation, 1999, 4, 318.	14 rgBT / 0.8	Overlock 10 0
250	Complete Reversion of Familial Adenomatous Polyposis Phenotype Associated with Tacrolimus and Mycophenolate Mofetil Treatment Following Kidney Transplantation. Anticancer Research, 2017, 37, 3105-3109.	0.5	1
251	Cytokine storm is the cryptic killer behind coronavirus disease-2019 infections, review of the current evidence to identify therapeutic options. Reviews in Medical Microbiology, 2021, 32, 57-65.	0.4	1
252	Tacrolimus Induced Diabetes Presenting As Recurrent Pyelonephritis – A Rare Clinical Presentation. European Journal of Medical and Health Sciences, 2020, 2, .	0.1	0
253	Application of a newly-developed cynomolgus macaque BiTE-mediated cytotoxic T-lymphocyte activity assay to various immunomodulatory agents inÂvitro. Journal of Immunotoxicology, 2021, 18, 154-162.	0.9	1
254	Systemic Immunosuppression for Prevention of Recurrent Tendon Adhesions. Plastic and Reconstructive Surgery - Global Open, 2021, 9, e3834.	0.3	1
255	The identification of dominant epitopes of h-FKBP-12 recognized by monoclonal antibodies, 3F4 and 2C1, against h-FK-506 binding protein 12(h-FKBP-12). , 1999, , 803-804.		0
256	Clinical Use of Immunosuppressive Drugs to Control the Immune Response. , 2007, , 391-407.		0
257	Tekrarlayan gebelik kaybı ve implantasyon başarısızlıklarında immünolojik problemlerin yeri. Türk Sağlığı Ve Neonatoloji Dergisi, 0, , .	Kadın 0.0	0
258	Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review. Current Drug Therapy, 2020, 15, 283-298.	0.2	3
259	Immunosuppressants FK506 and rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation. Biochemical Journal, 1999, 344 Pt 3, 803-12.	1.7	1
260	Dry eye: an inflammatory ocular disease. Journal of Ophthalmic and Vision Research, 2014, 9, 240-50.	0.7	116
261	Engineering β Cell Replacement Therapies for Type 1 Diabetes: Biomaterial Advances and Considerations for Macroscale Constructs. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 485-513.	9.6	7
262	Thermosensitive Polyester Hydrogel for Application of Immunosuppressive Drug Delivery System in Skin Allograft. Gels, 2021, 7, 229.	2.1	5
263	High antibody response in relation to immunosuppressive blood levels in liver transplant recipients after SARS-CoV-2 vaccination: an observational, cohort study. Gut, 2022, 71, 2605-2608.	6.1	3

#	Article	IF	CITATIONS
265	Bioprocessing strategies for microbial production and purification of immunosuppressants: An insight for process intensification. Chemical Engineering and Processing: Process Intensification, 2022, 172, 108797.	1.8	0
266	Management of Chronic Graft-vsHost Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan. Frontiers in Pediatrics, 2022, 10, 808103.	0.9	8
267	Transcriptional analysis of lung fibroblasts identifies PIM1 signaling as a driver of aging-associated persistent fibrosis. JCI Insight, 2022, 7, .	2.3	22
268	Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma. Pharmacological Research, 2022, 178, 106181.	3.1	14
269	miR-731 modulates the zebrafish heart morphogenesis via targeting Calcineurin/Nfatc3a pathway. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130133.	1.1	0
270	The Proteomic Signature of Intestinal Acute Rejection in the Mouse. Metabolites, 2022, 12, 23.	1.3	3
271	Investigating the potential of Quercetin enthused nano lipoidal system for the management of dermatitis. Research Journal of Pharmacy and Technology, 2021, , 6516-6526.	0.2	2
272	Immunosuppression Therapy in Kidney Transplantation. Urologic Clinics of North America, 2022, 49, 345-360.	0.8	4
273	The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients. European Journal of Clinical Pharmacology, 2022, , .	0.8	1
274	The Effect of Presurgical and Postsurgical Topical Tacrolimus on Pedicled Flap Survival in Rats. Annals of Plastic Surgery, 2022, 88, S235-S238.	0.5	0
276	Drug-induced digestive tract injury: decoding some invisible offenders. Human Pathology, 2023, 132, 135-148.	1.1	2
277	A clinical case of Streptococcus equi subsp. ruminatorum infection in a 9-year-old child. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2022, 67, 127-131.	0.1	0
278	Low-Dose Tacrolimus Promotes the Migration and Invasion and Nitric Oxide Production in the Human-Derived First Trimester Extravillous Trophoblast Cells In Vitro. International Journal of Molecular Sciences, 2022, 23, 8426.	1.8	1
279	Current status of xenotransplantation research and the strategies for preventing xenograft rejection. Frontiers in Immunology, 0, 13, .	2.2	13
280	Tacrolimus-Eluting Disk within the Allograft Enables Vascularized Composite Allograft Survival with Site-Specific Immunosuppression without Systemic Toxicity. Pharmaceutical Research, 0, , .	1.7	1
281	Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort. Viruses, 2022, 14, 1766.	1.5	13
282	Fast Tacrolimus Metabolism Does Not Promote Post-Transplant Diabetes Mellitus after Kidney Transplantation. International Journal of Molecular Sciences, 2022, 23, 9131.	1.8	4
283	Neutropenia in pediatric solid organ transplant. Pediatric Transplantation, 2022, 26, .	0.5	0

ARTICLE IF CITATIONS Management of Atopic Dermatitis: The Role of Tacrolimus. Cureus, 2022, , . 0.2 4 284 Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic 1.0 Telangiectasia: An Open-Label, Pilot Study. Journal of Clinical Mediciné, 2022, 11, 5280. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria 286 1.0 10 Group. Maturitas, 2022, 166, 65-85. Tacrolimus (FK506) treatment of CD34 ⁺ hematopoietic progenitor cells promote the development of dendritic cells that drive CD4 ⁺ T cells toward Th2 responses. Journal of Leukocyte Biology, 2000, 68, 633-640. Postoperative review of care for heart transplant recipients. Journal of Cardiothoracic and Vascular 288 0.6 0 Anesthesia, 2022, , . Progress and challenges in the biofoundry of immunosuppressants: From process to practice. 1.7 Biotechnology and Bioengineering, 0, , . New approaches in the treatment of stable segmental vitiligo: a randomized, prospective pilot study for comparison of a triple combination of 2940nm Er: <scp>YAG</scp> laser and triamcinolone acetonide solution with either 308nm excimer laser or 0.1% tacrolimus. Dermatologic Therapy, 0, , . 290 0.8 1 Prolongation of graft survival via layer-by-layer assembly of collagen and immunosuppressive 5.7 particles on pancreatic islets. Biomaterials, 2022, 290, 121804. 292 Therapeutic Drug Monitoring and Toxicology: Relevance of Measuring Metabolites., 2022, , 197-232. 0 Homing of vertebralâ€delivered mesenchymal stromal cells for degenerative intervertebral discs repair 1.5 – an in vivo proofâ€ofâ€concept study. JOR Spine, 2023, 6, . Biosensing Tacrolimus in Human Whole Blood by Using a Drug Receptor Fused to the Emerald Green 294 3.2 5 Fluorescent Protein. Analytical Chemistry, 2022, 94, 16337-16344. T cells in ocular autoimmune uveitis: Pathways and therapeutic approaches. International Immunopharmacology, 2023, 114, 109565. Local delivery of tacrolimus using electrospun poly-ĵu-caprolactone nanofibres suppresses the T-cell 296 1.8 0 response to peripheral nerve allografts. Journal of Neural Engineering, 0, , . Redox-Responsive Hyaluronic Acid–Tacrolimus Conjugate: Synthesis, Characterization, and <i>In Vitro</i> Immunosuppressive Activity. ACS Applied Bio Materials, 2023, 6, 733-744. 2.3 Dynamics of Humoral and Cellular Responses in Renal Transplant Recipients Receiving 3 Doses of 298 0.54 SÁRS-CoV-2 mRNA Vaccine. Transplantation, 0, Publish Ahead of Print, . 299 Netherton syndrome in aÂBulgarian patient. Wiener Medizinische Wochenschrift, 0, , . Intestinal Transplant Immunology and Intestinal Graft Rejection: From Basic Mechanisms to Potential 300 1.8 4 Biomarkers. International Journal of Molecular Sciences, 2023, 24, 4541. Combination of Lactobacillus plantarum improves the effects of tacrolimus on colitis in a mouse 301 1.8 model. Frontiers in Cellular and Infection Microbiology, 0, 13, .

#	Article	IF	Citations
302	A Multi-Centre Non-Interventional Study to Assess the Tolerability and Effectiveness of Extended-Release Tacrolimus (LCPT) in De Novo Liver Transplant Patients. Journal of Clinical Medicine, 2023, 12, 2537.	1.0	1
308	Drugs Used Post stem Cell Transplant. , 2023, , 661-685.		0
312	Main Issues to Overcome in Modern Penetrating Keratoplasty. Essentials in Ophthalmology, 2023, , 71-101.	0.0	0
323	Post-Heart Transplant Care and Long-Term Complications in Children. , 2023, , 1-40.		0